Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07250724

A Prospective Observational Study Evaluating C. Difficile Toxin Levels in Stool After Standard Antibiotic Treatment for Clostridioides difficile Infection Recurrence

Led by Bactolife A/S · Updated on 2026-05-28

60

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to understand the risk of recurrence of Clostridioides difficile infection (CDI) after initial antibiotic treatment for a first recurrence. It focuses on adults who have completed standard antibiotic therapy for their first recurrent CDI and are currently asymptomatic. The study will evaluate how often CDI returns within eight weeks and whether levels of C. difficile toxins A and B in stool can predict this risk. Participants will be followed after finishing their standard oral antibiotic treatment for CDI. The study includes four clinic visits over about nine weeks, which can also be done remotely by phone. Stool samples will be collected at baseline, week 2, and week 8 to measure toxin levels using sensitive tests. This observational study seeks to explore the connection between toxin presence after treatment and the chance of infection returning. During the study, participants will provide stool samples and undergo assessments at scheduled visits. Researchers will monitor for CDI recurrence during the eight-week follow-up and analyze toxin levels in stool samples. The main outcome measured is the proportion of participants experiencing CDI recurrence within this period. Participants’ health and safety will be observed throughout the study, which lasts approximately nine weeks.

CONDITIONS

Brief Title

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide signed and dated informed consent
  • Males and females between 18 and 75 years old inclusive
  • Documented history of first recurrent Clostridioides difficile infection with positive toxin test within the past 12 months
  • Completed standard oral antibiotic therapy for the first recurrent CDI within 5 days before enrollment
  • No CDI-related symptoms at the time of enrollment
Not Eligible

You will not qualify if you...

  • Current episode of CDI or unresolved symptoms from previous recurrence
  • Positive test for Toxin A only without Toxin B
  • Planned CDI treatments during the study like fecal microbiome transplant or probiotics
  • Receiving additional antibiotic treatments after initial rCDI therapy
  • Pregnant, lactating, or planning pregnancy within 3 months
  • Active diarrhea with 3 or more stools per day and Bristol stool scale 5-7 at baseline
  • Significant acute or chronic health conditions that risk safety or confound results
  • Use of parenteral nutrition or ostomy
  • Active pancreatitis or uncontrolled intestinal diseases like IBS, IBD, Crohn's disease, ulcerative colitis, or celiac disease
  • Taking medications that interfere with study objectives or pose safety risks
  • Unlikely to comply with study requirements
  • Currently participating in other clinical studies or insufficient time since last experimental study participation to ensure result integrity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) to provide informed consent and stool sample for testing

Monitoring

Duration - 8 weeks

Participants who have completed standard antibiotic treatment for Clostridioides difficile infection are observed to assess stool toxin levels and monitor for infection recurrence.

3 visits at baseline, Week 2, and Week 8 for stool sample collection and assessments

Trial Site Locations

Total: 1 location

1

Emory University Hospital

Atlanta, Georgia, United States, 30322

Actively Recruiting

Loading map...

Research Team

K

Kevin O' Regan Senior Operations Manager, Atlantia Clinical Trials

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Assessment of Changes in Gut Microbiota of Patients With Rec...

Clostridioides Difficile Infection Recurrence

Actively Recruiting

1 location

Fecal Microbiota (FMT) Oral Capsules in the Treatment of Rec...

Clostridioides Difficile Infection Recurrence

Actively Recruiting

1 location

Secondary Prophylaxis of Recurrent Clostridioides Difficile ...

Clostridioides Difficile Infection

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here